The FDA on April 17, 2018 approved TAVALISSE® for the treatment of thrombocytopenia in adult patients with chronic Immune Thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. TAVALISSE® is a product of Rigel Pharmaceuticals, Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
